ValuEngine upgraded shares of HealthEquity (NASDAQ:HQY) from a buy rating to a strong-buy rating in a research report report published on Tuesday morning.
A number of other research analysts have also issued reports on HQY. JPMorgan Chase dropped their target price on HealthEquity from $52.00 to $51.00 and set an overweight rating on the stock in a report on Wednesday, January 24th. Robert W. Baird boosted their target price on HealthEquity from $48.00 to $49.00 and gave the company a neutral rating in a report on Wednesday, February 7th. Cantor Fitzgerald boosted their target price on HealthEquity from $56.00 to $60.00 and gave the company an overweight rating in a report on Wednesday, February 7th. Zacks Investment Research raised HealthEquity from a hold rating to a buy rating and set a $57.00 target price on the stock in a report on Saturday, February 10th. Finally, BidaskClub raised HealthEquity from a hold rating to a buy rating in a report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $68.30.
Get HealthEquity alerts:
HealthEquity opened at $74.86 on Tuesday, Marketbeat.com reports. The company has a market capitalization of $4.49 billion, a PE ratio of 138.63, a P/E/G ratio of 2.95 and a beta of 1.39. HealthEquity has a 12-month low of $40.21 and a 12-month high of $76.76.
HealthEquity (NASDAQ:HQY) last released its earnings results on Monday, March 19th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.06. The business had revenue of $60.44 million for the quarter, compared to analyst estimates of $58.46 million. HealthEquity had a return on equity of 13.47% and a net margin of 20.64%. sell-side analysts forecast that HealthEquity will post 0.77 EPS for the current year.
In related news, CMO Gary D. Robinson sold 500 shares of the company’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $64.00, for a total transaction of $32,000.00. Following the transaction, the chief marketing officer now owns 3,490 shares of the company’s stock, valued at $223,360. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Darcy G. Mott sold 9,500 shares of the company’s stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $61.02, for a total value of $579,690.00. Following the completion of the sale, the vice president now directly owns 105,500 shares in the company, valued at approximately $6,437,610. The disclosure for this sale can be found here. Insiders have sold 541,842 shares of company stock worth $36,942,900 in the last ninety days. 4.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Citigroup Inc. grew its holdings in HealthEquity by 414.4% in the first quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock valued at $160,000 after purchasing an additional 2,126 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new stake in HealthEquity in the fourth quarter valued at $149,000. WINTON GROUP Ltd acquired a new stake in HealthEquity in the first quarter valued at $206,000. M&T Bank Corp acquired a new stake in HealthEquity in the first quarter valued at $206,000. Finally, Parametrica Management Ltd acquired a new stake in HealthEquity in the first quarter valued at $220,000. 98.54% of the stock is currently owned by institutional investors.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
To view ValuEngine’s full report, visit ValuEngine’s official website.